The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents
Open accessAbstract
Background: Resistance to all first-line antibiotics necessitates the use of less effective or more toxic “reserve” agents. Gram-negative bloodstream infections (GNBSIs) harboring such difficult-to-treat resistance (DTR) may have higher mortality than phenotypes that allow for ≥1 active first-line antibiotic. Methods: The Premier Database was analyzed for inpatients with select GNBSIs. DTR was defined as intermediate/resistant in vitro to all ß-lactam categories, including carbapenems and fluoroquinolones. Prevalence and aminoglycoside resistance of DTR episodes were compared with carbapenem-resistant, extended-spectrum cephalosporin-resistant, and fluoroquinolone-resistant episodes using CDC definitions. Predictors of DTR were identified. The adjusted relative risk (aRR) of mortality was examined for DTR, CDC-defined phenotypes susceptible to ≥1 first-line agent, and graded loss of active categories. Results: Between 2009–2013, 471 (1%) of 45011 GNBSI episodes at 92 (53.2%) of 173 hospitals exhibited DTR, ranging from 0.04% for Escherichia coli to 18.4% for Acinetobacter baumannii. Among patients with DTR, 79% received parenteral aminoglycosides, tigecycline, or colistin/polymyxin-B; resistance to all aminoglycosides occurred in 33%. Predictors of DTR included urban healthcare and higher baseline illness. Crude mortality for GNBSIs with DTR was 43%; aRR was higher for DTR than for carbapenem-resistant (1.2; 95% confidence interval, 1.0–1.4; P = .02), extended-spectrum cephalosporin-resistant (1.2; 1.1–1.4; P = .001), or fluoroquinolone-resistant (1.2; 1.0–1.4; P = .008) infections. The mortality aRR increased 20% per graded loss of active first-line categories, from 3–5 to 1–2 to 0. Conclusion: Nonsusceptibility to first-line antibiotics is associated with decreased survival in GNBSIs. DTR is a simple bedside prognostic measure of treatment-limiting coresistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
(2013) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/103.1437-1588 · Cited by 11,796
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Global Spread of Carbapenemase-producing Enterobacteriaceae
Nordmann, P., Naas, T., & Poirel, L. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110655 · Cited by 2,378
Cosgrove, S. E. (2006) · Clinical Infectious Diseases · doi:10.1086/499406 · Cited by 1,271
Cosgrove, S. E., Qi, Y., Kaye, K. S., Harbarth, S., Karchmer, A. W., & Carmeli, Y. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502522 · Cited by 856
Roberts, R. R., Hota, B., Ahmad, I., Scott II, R. D., Foster, S. D., Abbasi, F., Schabowski, S., Kampe, L. M., Ciavarella, G. G., Supino, M., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/605630 · Cited by 705
The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection
Leibovici, Shraga, Drucker, Konigsberger, Samra, Pitlik, & Pitlik (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00379.x · Cited by 685
Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
Falagas, M. E., Tansarli, G. S., Karageorgopoulos, D. E., & Vardakas, K. Z. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.121004 · Cited by 514
Lambert, M.-L., Suetens, C., Savey, A., Palomar, M., Hiesmayr, M., Morales, I., Agodi, A., Frank, U., Mertens, K., Schumacher, M., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70258-9 · Cited by 443
Tabah, A., Koulenti, D., Laupland, K., Misset, B., Valles, J., Bruzzi de Carvalho, F., Paiva, J. A., Çakar, N., Ma, X., Eggimann, P., et al. (2012) · Intensive Care Medicine · doi:10.1007/s00134-012-2695-9 · Cited by 436
Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013
Guh, A. Y., Bulens, S. N., Mu, Y., Jacob, J. T., Reno, J., Scott, J., Wilson, L. E., Vaeth, E., Lynfield, R., Shaw, K. M., et al. (2015) · JAMA · doi:10.1001/jama.2015.12480 · Cited by 369
McGann, P., Snesrud, E., Maybank, R., Corey, B., Ong, A. C., Clifford, R., Hinkle, M., Whitman, T., Lesho, E., & Schaecher, K. E. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01103-16 · Cited by 350
Hygienemaßnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen Stäbchen
(2012) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-012-1549-5 · Cited by 326
Excess Deaths Associated With Tigecycline After Approval Based on Noninferiority Trials
Prasad, P., Sun, J., Danner, R. L., & Natanson, C. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis270 · Cited by 298
Self-citationSatlin, M. J., Jenkins, S. G., & Walsh, T. J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu052 · Cited by 255
Cohen, A. L., Calfee, D., Fridkin, S. K., Huang, S. S., Jernigan, J. A., Lautenbach, E., Oriola, S., Ramsey, K. M., Salgado, C. D., Weinstein, R. A., et al. (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591741 · Cited by 179
Self-citationBaram, D., Daroowalla, F., Garcia, R., Zhang, G., Chen, J. J., Healy, E., Riaz, S. A., & Richman, P. S. (2008) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s544 · Cited by 150
Zilberberg, M. D., Nathanson, B. H., Sulham, K., Fan, W., & Shorr, A. F. (2016) · Critical Care · doi:10.1186/s13054-016-1392-4 · Cited by 135
Lye, D. C., Earnest, A., Ling, M. L., Lee, T.-E., Yong, H.-C., Fisher, D. A., Krishnan, P., & Hsu, L. Y. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03606.x · Cited by 117
Measuring the impact of multidrug resistance in nosocomial infection
Blot, S. I., Depuydt, P. O., Vandewoude, K., & Bacquer, D. D. (2007) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32818be6f7 · Cited by 117
Vicari, G., Bauer, S. R., Neuner, E. A., & Lam, S. W. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis909 · Cited by 107
Burnham, J. P., Lane, M., & Kollef, M. H. (2015) · Critical Care Medicine · doi:10.1097/ccm.0000000000001013 · Cited by 71
Mechanisms of carbapenem resistance in cephalosporin-susceptible Pseudomonas aeruginosa in China
Zeng, Z., Wang, W., Huang, M., Shi, L.-N., Wang, Y., & Shao, H. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.11.014 · Cited by 44
Wong, P. H. P., von Krosigk, M., Roscoe, D. L., Lau, T. T. Y., Yousefi, M., & Bowie, W. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-393 · Cited by 36
Bloodstream infections in ICU with increased resistance: epidemiology and outcomes.
Dimopoulos, G., Koulenti, D., Tabah, A., Poulakou, G., Vesin, A., Arvaniti, K., Lathyris, D., Matthaiou, D. K., Armaganidis, A., & Timsit, J. (2015) · PubMed · Cited by 24
Emerging Infections Program as Surveillance for Antimicrobial Drug Resistance
Fridkin, S. K., Cleveland, A. A., See, I., & Lynfield, R. (2015) · Emerging infectious diseases · doi:10.3201/eid2109.150512 · Cited by 19
Self-citation
Cited by
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Paul, M., Carrara, E., Retamar, P., Tängdén, T., Bitterman, R., Bonomo, R. A., de Waele, J., Daikos, G. L., Akova, M., Harbarth, S., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.025 · Cited by 1,056
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac268 · Cited by 526
Metadata
- Authors
- Kadri, S. S., Adjemian, J., Lai, Y. L., Spaulding, A. B., Ricotta, E., Prevots, D. R., Palmore, T. N., Rhee, C., Klompas, M., Dekker, J. P., Powers, J. H., Suffredini, A. F., Hooper, D. C., Fridkin, S., Danner, R. L., & (NIH–ARORI), N. I. O. H. A. R. O. R. I.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-07-23
- Volume
- 67
- Issue
- 12
- Pages
- 1803-1814
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2883234304
- Cited by
- 605
- References
- 29
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.